17,261 trials
Multiple Myeloma
Primary: Rate of Patients Achieving a Response Based on M-protein or Free Light Chains — 0; 1 participants
Obsessive-compulsive Disorder · Ocd
Primary: Partial Responders by Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) — 5; 2 participants — p=.24
Neurofibromatosis 2 · Vestibular Schwannoma
Primary: Estimated Volumetric Progression Free Survival at 12 Months — 70.6 Liklihood of PFS at 12 months
Neoplasms, Breast
Primary: Percentage of Participants With Pathological Complete Response (pCR) in the Breast and in the Lymph Nodes — 25; 26.3; 46.7 Percentage of participants — p=0.019
Schizophrenia
Primary: Number of Patients With Adverse Events as a Measure of Safety and Tolerability — 12; 8; 4; 4 participants
HIV Infections
Primary: The Proportion Of Participants With Virologic Response For 10 mg/Day Elvucitabine In HIV-1-Infected Participants By 12 Weeks Compared With The Proportion Of Participants…
Restless Leg Syndrome
Primary: Mean Total Restless Leg Syndrome Rating Scale Score — 25.19; 19.46 units on a scale — p=0.031
Macular Degeneration
Primary: Mean Change in Visual Acuity (Logarithm of the Minimum Angle of Resolution [LogMAR]) Score From Baseline for IGIV-C, 10% Compared to Placebo at Week 12 or at Last LogMAR…
Estrogen Receptor Negative · HER2/Neu Negative · Progesterone Receptor Negative
Primary: PFS Status — 1.2 months
Hypothalamic Obesity
Primary: BMI Change — -0.77 kg/m^2 — p=.05
Recurrent Melanoma · Stage IV Skin Melanoma
Primary: Objective Response Rate — 1; 0; 6 patients
Depression
Primary: Montgomery Asberg Depression Rating Scale — 9.5 units on a scale
Chronic Kidney Disease · Cardiovascular Disease
Primary: Change in the Concentration of High Sensitivity C-Reactive Protein (hsCRP) From Baseline to 12 Weeks — -2.6; 0.8 mg/dl — p=0.03
Male Breast Carcinoma · Recurrent Breast Carcinoma · Stage IIIC Breast Cancer AJCC v7
Primary: Confirmed Response Rate (Percentage of Participants With Complete or Partial Response Noted as the Objective Status on Two Consecutive Evaluations at Least 4 Weeks…
Prostate Cancer
Primary: Freedom From Biochemical/Clinical Failure (FFF) — 20; 21 participants